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Abstract: L-Carnitine is an important co-factor in fatty acid metabolism by mitochondria. This study has determined
whether oral administration of L-carnitine prevents remodelling and the development of impaired cardiovascular function in
deoxycorticosterone acetate (DOCA)-salt hypertensive rats (n = 6–12; #p < 0.05 versus DOCA-salt). Uninephrectomized rats
administered DOCA (25 mg every 4th day s.c.) and 1% NaCl in drinking water for 28 days developed cardiovascular remodel-
ling shown as systolic hypertension, left ventricular hypertrophy, increased thoracic aortic and left ventricular wall thickness,
increased left ventricular inflammatory cell infiltration together with increased interstitial collagen and increased passive dia-
stolic stiffness and vascular dysfunction with increased plasma malondialdehyde concentrations. Treatment with L-carnitine
(1.2% in food; 0.9 mg ⁄ g ⁄ day in DOCA-salt rats) decreased blood pressure (DOCA-salt 169 € 2; + L-carnitine 148 € 6#
mmHg), decreased left ventricular wet weights (DOCA-salt 3.02 € 0.07; + L-carnitine 2.72 € 0.06# mg ⁄ g body-wt), decreased
inflammatory cells in the replacement fibrotic areas, reduced left ventricular interstitial collagen content (DOCA-salt
14.4 € 0.2; + L-carnitine 8.7 € 0.5# % area), reduced diastolic stiffness constant (DOCA-salt 26.9 € 0.5; + L-carnitine
23.8 € 0.5# dimensionless) and decreased plasma malondialdehyde concentrations (DOCA-salt 26.9 € 0.8; + L-carnitine
21.2 € 0.4# lmol ⁄ l) without preventing endothelial dysfunction. L-carnitine attenuated the cardiac remodelling and improved
cardiac function in DOCA-salt hypertension but produced minimal changes in aortic wall thickness and vascular function.
This study suggests that the mitochondrial respiratory chain is a significant source of reactive oxygen species in the heart but
less so in the vasculature in DOCA-salt rats, underlying the relatively selective cardiac responses to L-carnitine treatment.
Mitochondrial oxidative catabolism of fatty acids is a major
energy source for the adult mammalian heart although ele-
vated serum fatty acid concentrations and enhanced fatty
acid use have been implicated in the pathogenesis of heart
failure [1]. The naturally occurring amino acid, l-carnitine,
plays a major role, as a cofactor, in the transportation of free
fatty acids from the cytosol to the mitochondria, their degra-
dation to acyl-CoA by b-oxidation and their subsequent
entry into the tricarboxylic acid cycle to produce adenosine
triphosphate through oxidative phosphorylation [2]. Further-
more, l-carnitine regulates carbohydrate metabolism in the
mitochondria by modulating the acetyl-CoA:CoA ratio.
l-carnitine, produced primarily in the liver and kidneys from
l-lysine and l-methionine, is found in high concentrations in
animal skeletal and cardiac muscles with red meat and dairy
products as the most common dietary sources. Decreased
l-carnitine concentrations will lead to dysfunction of the
mitochondrial respiratory chain, which can further cause
cardiovascular disease [3]. l-Carnitine treatment restored car-
diac l-carnitine concentrations and improved heart recovery
after ischaemia and reperfusion through counteracting the
toxic effects of high concentrations of free fatty acids, and
also through improving carbohydrate metabolism [4].
Further, l-carnitine treatment improved cardiovascular
parameters in patients with secondary carnitine deficiency
following haemodialysis for kidney disease [5].
Damage to the heart and vascular system is associated
with increased production of reactive oxygen species such as
superoxide and hydrogen peroxide producing hypertension,
endothelial damage, cardiac hypertrophy, inflammation, ath-
erosclerosis, ventricular contractile dysfunction and fibrosis
[6]. Rat models of mineralocorticoid hypertension such as
the deoxycorticosterone acetate (DOCA)-salt or aldosterone-
salt hypertensive rat [7] produced similar results, following
endothelin-induced increases in vascular and cardiac super-
oxide production by NADPH oxidase [8–10]. Selective ETA
receptor antagonists such as A-127722 prevented and
reversed the cardiovascular remodelling and improved func-
tion [11]. If the mitochondrial respiratory chain is also a
major source of reactive oxygen species in this model leading
to cardiovascular remodelling, then normalization of the
function of the chain should be effective in preventing car-
diovascular damage.
The aim of this project was to determine whether oral
administration of l-carnitine to DOCA-salt hypertensive rats
prevents or attenuates the development of structural and
functional changes in the heart and blood vessels. Structural
changes were characterized by histology while heart function
was measured ex vivo in isolated perfused hearts. Isolated
thoracic aortic rings were used to measure vascular reactivity.
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Materials and Methods
DOCA-salt hypertensive rats. Male Wistar rats (8–10 weeks old) were
obtained from the Central Animal Breeding House of The University
of Queensland. All experimental protocols were approved by the Ani-
mal Experimentation Ethics Committee of The University of Queens-
land under the guidelines of the National Health and Medical
Research Council, Australia. Rats were given ad libitum access to food
and water and were housed in 12-hr. light:dark conditions. All treated
rats were uninephrectomized. Rats were anaesthetized with an intra-
peritoneal injection of Zoletil" [Virbac (Australia) Pty Ltd, Milperra,
NSW, Australia] (25 mg ⁄ kg each of tiletamine and zolazepam) and
Ilium Xylazil (Troy Laboratories, Smithfiled, NSW, Australia) (xyla-
zine, 10 mg ⁄ kg). A lateral abdominal incision provided access to the
left kidney, its renal vessels and ureter. The renal vessels and ureter
were ligated; the left kidney was removed for weighing and the incision
site was sutured. Uninephrectomized rats were either given no further
treatment or were given 1% NaCl in drinking water together with sub-
cutaneous injections of DOCA (25 mg in 0.4 ml dimethylformamide)
every 4th day (DOCA-salt rats) [11–14]. L-Carnitine was administered
as a 1.2%mixture in powdered food for a total period of 32 days start-
ing 4 days before surgery and ending 28 days after surgery.
Assessment of physiological parameters. Body-weight, food and water
intakes were measured daily. Systolic blood pressure was measured
at week 0 and at the end of weeks 2 and 4 under light sedation with
i.p. injection of Zoletil" (tiletamine 15 mg ⁄ kg, zolazepam
15 mg ⁄ kg), using an MLT1010 Piezo-Electric Pulse Transducer
(ADInstruments, Sydney, Australia) and inflatable tail-cuff con-
nected to an MLT844 Physiological Pressure Transducer (ADInstru-
ments) and PowerLab data acquisition unit (ADInstruments). Rats
were killed with an injection of pentobarbitone sodium (100 mg ⁄ kg
i.p.). Blood was taken from the abdominal aorta and centrifuged,
and the plasma was frozen. Plasma malondialdehyde concentrations,
as a measure of oxidative stress, were determined by HPLC [13].
Isolated heart preparation. The left ventricular function of the rats in
all groups was assessed using the Langendorff heart preparation
[11–14]. Once terminal anaesthesia was achieved with pentobarbitone
sodium (100 mg ⁄ kg i.p.), heparin (1000 IU) was injected into the right
femoral vein. Isovolumetric ventricular function was measured by
inserting a latex balloon catheter into the left ventricle connected to a
Capto SP844 MLT844 physiological pressure transducer and Chart
software on aMaclab system (ADInstruments, Sydney, Australia). All
left ventricular end-diastolic pressure values were measured by pacing
the heart at 250 beats ⁄min. using an electrical stimulator. End-dia-
stolic pressureswere obtained starting from 0 mmHg up to 30 mmHg.
To assess contractile function, time derivatives of pressure (+dP ⁄ dt;
)dP ⁄ dt) were calculated at a diastolic pressure of 10 mmHg. The right
and left ventricles were separated and weighed. Diastolic stiffness con-
stant (j, dimensionless) was calculated as in previous studies [11–14].
Organ bath studies. Thoracic aortic rings (4 mm in length) were sus-
pended in an organ bath chamber with a resting tension of 10 mN.
Cumulative concentration-response (contraction) curves were mea-
sured for noradrenaline; concentration-response (relaxation) curves
were measured for acetylcholine and sodium nitroprusside in the
presence of a submaximal (70%) contraction to noradrenaline [15].
Contractile responses to noradrenaline were evaluated previously fol-
lowing pre-contraction and wash with isotonic KCl (100 mM) in the
DOCA-salt rats [15].
Organ weights. Following euthanasia, the heart, liver, kidneys and
spleen were removed and blotted dry for weighing. Organ weights
were normalized relative to the body-weight at the time of their
removal (in mg ⁄ g).
Histology. Tissues were initially fixed for 3 days in Telly’s fixative
(100 ml of 70% ethanol, 5 ml of glacial acetic acid and 10 ml of 40%
formaldehyde) and then transferred into modified Bouin’s fluid
(85 ml of saturated picric acid, 5 ml glacial acetic acid and 10 ml of
40% formaldehyde) for 2 days. The samples were then dehydrated
and embedded in paraffin wax. Thin sections (10 lm) of left ventri-
cle, stained with haematoxylin and eosin, were used for determina-
tion of inflammatory cell infiltration while thick sections (15 lm) of
left ventricle and thoracic aorta, stained with picrosirius red, were
used to measure collagen distribution [13]. All sections were analysed
under a laser confocal microscope as previously described [13].
Statistical analysis. All data sets were represented as mean € stan-
dard error of mean (S.E.M.). Comparisons or findings between
groups were made via statistical analysis of data sets using one-
way ⁄ two-way analysis of variance followed by the Duncan test to
determine differences between treatment groups. A p-value of <0.05
was considered as statistically significant.
Drugs. Deoxycorticosterone acetate, heparin, noradrenaline, acetyl-
choline and sodium nitroprusside were purchased from Sigma Chem-
ical Company (St Louis, MO, USA). L-Carnitine was purchased
from Musashi Pty Ltd, Gold Coast, Queensland, Australia. Nor-
adrenaline hydrochloride, acetylcholine chloride and sodium nitro-
prusside were dissolved in distilled water. DOCA was dissolved in
dimethylformamide with mild heating.
Results
Biometrics.
DOCA-salt treated rats showed an increase inwater intake and
failed to gain weight compared to uninephrectomized (UNX)
rats as controls (fig. 1). L-Carnitine failed to alter body-weight
(fig. 1) or water intake in the DOCA-salt rats. There was no
change in the food intake among the groups. Thus, L-carnitine
intake was unchanged in the treated DOCA-salt
(0.9 € 0.1 mg ⁄g ⁄day) and UNX (1.1 € 0.1 mg ⁄ g ⁄day) rats.
Systolic blood pressure was increased in DOCA-salt rats when
compared with UNX rats and this increase was attenuated by
L-carnitine treatment (table 1). The DOCA-salt rats showed
left and right ventricular hypertrophy (seen as increased left
ventricle + septum and right ventricular wet weights) at
4 weeks, compared with UNX rats and this increase in wet
weight of left ventricle but not the right ventricle was atten-
uated by L-carnitine treatment (table 1). The increased wet





















Fig. 1. Daily body-weight measurements for UNX ( ),
UNX + l-carnitine (h), DOCA-salt (s) and DOCA-salt + l-
carnitine (d)-treated rats (*p < 0.05 versus UNX).
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weight of the remnant kidney seen in DOCA-salt rats was
also attenuated by L-carnitine treatment (table 1). Plasma
malondialdehyde concentrations were increased after
4 weeks of DOCA-salt hypertension; this change was pre-
vented by L-carnitine treatment (table 1).
Left ventricular structure and function.
In comparison to UNX rats, collagen content was increased
in the left ventricles of DOCA-salt rats (table 1, figs 2A and
B). L-Carnitine treatment did not alter collagen content in
UNX rats (table 1, fig. 2C) but attenuated the increased col-
lagen deposition in DOCA-salt rats (table 1, fig. 2D). Hearts
from DOCA-salt rats showed significantly increased diastolic
stiffness that was attenuated by L-carnitine treatment
(table 1). The functional parameters, +dP ⁄dt (ventricular
contraction) and )dP ⁄dt (ventricular relaxation), were
unchanged compared to UNX rats; L-carnitine treatment did
not alter these parameters (table 1).
Left ventricular monocyte ⁄macrophage infiltration.
Infiltrating inflammatory cells occurred in low numbers and
always as single cells in the left ventricles of UNX rats
(fig. 3A). Many more inflammatory cells were observed in
the left ventricle sections of DOCA-salt rats, and these cells
were usually found in clusters of cells located throughout the
interstitium and especially at scar sites and areas of fibrosis
(fig. 3B). Treatment with L-carnitine did not change the den-
sity of inflammatory cells in UNX rats (fig. 3C) but mark-
edly reduced inflammatory cell infiltration and the overall
area of scar tissue in DOCA-salt hypertensive rats (fig. 3D).
However, some inflammatory cells were still found within the
interstitial component of the left ventricle.
Vascular structure and function.
Thoracic aortic rings showed an increased wall thickness in
DOCA-salt rats that was not reduced by L-carnitine treatment
(table 1; fig. 4). Thoracic aortic rings from DOCA-salt hyper-
tensive rats showed an increased potency with unaltered maxi-
mal responses to noradrenaline across all treatment groups. In
previous studies, we showed no differences between the maxi-
mal contractile responses to KCl (100 mM) (9.1 € 1.4 mN;
n = 15) and to noradrenaline (1 · 10)5 M) (7.7 € 2.2 mN;
n = 7) in thoracic aortic rings from the DOCA-salt rats
(Brown L, unpublished data). Treatment with L-carnitine did
not modify responses to noradrenaline (fig. 5A). Further-
more, relaxant responses to sodium nitroprusside were
unchanged among the groups (fig. 5B). Relaxant responses to
acetylcholine were reduced in DOCA-salt rats; treatment with
L-carnitine did not prevent this damage (fig. 5C).
Discussion
Cardiovascular remodelling includes hypertension, endothe-
lial damage, cardiac hypertrophy, inflammation, ventricular
Table 1.
Physiological parameters of UNX, UNX + L-carnitine, DOCA-salt and DOCA-salt + L-carnitine-treated rats.
Parameter UNX UNX + l-carnitine DOCA-salt DOCA-salt + l-carnitine
Systolic blood pressure (mmHg) 122 € 3 (12) 125 € 1 (12) 169 € 2* (10) 148 € 6# (8)
LV weight (mg ⁄ g body-wt) 1.99 € 0.07 (8) 2.11 € 0.04 (12) 3.02 € 0.07* (12) 2.72 € 0.06# (11)
RV weight (mg ⁄ g body-wt) 0.50 € 0.03 (8) 0.53 € 0.03 (12) 0.60 € 0.03* (12) 0.61 € 0.04* (11)
Remnant kidney weight (mg ⁄ g body-wt) 4.80 € 0.16 (8) 4.81 € 0.35 (12) 9.48 € 0.48* (12) 8.47 € 0.29# (11)
Thoracic aortic wall thickness (lm) 72.3 € 5.3 (5) 71.6 € 2.7 (5) 111.3 € 2.8* (6) 104.2 € 2.6 (5)
Plasma malondialdehyde concentration (lmol ⁄ l) 18.7 € 1.0 (5) 20.3 € 0.7 (5) 26.9 € 0.8*(5) 21.2 € 0.4# (5)
LV perivascular collagen fraction (% area) 23.9 € 2.4 (4) 19.2 € 3.9 (4) 38.9 € 2.8* (6) 25.5 € 4.9# (5)
LV interstitial collagen fraction (% area) 6.0 € 0.4 (5) 6.1 € 0.2 (5) 14.4 € 0.2* (6) 8.7 € 0.5# (5)
Diastolic stiffness 21.7 € 0.5 (11) 20.7 € 0.5 (9) 26.9 € 0.5* (12) 23.8 € 0.5# (6)
+dP ⁄ dtmax (mmHg ⁄ sec.) 1890 € 260 (9) 1460 € 110 (6) 1710 € 170 (12) 1350 € 120 (6)
)dP ⁄ dtmax (mmHg ⁄ sec.) 1260 € 180 (9) 940 € 90 (6) 1160 € 130 (12) 890 € 90 (6)
Noradrenaline ()log EC50) 6.9 € 0.1 (6) 6.9 € 0.3 (6) 7.8 € 0.1* (6) 8.2 € 0.1* (6)
Values are mean € S.E.M.; number of experiments in parentheses. LV, left ventricle; RV, right ventricle. *p < 0.05 versus UNX; #p < 0.05 versus
DOCA.
A B C D
Fig. 2. Picrosirius red staining of left ventricular interstitial collagen deposition (magnification, ·40) in UNX (A), DOCA-salt (B), UNX +
l-carnitine (C), DOCA-salt + l-carnitine (D)-treated rats; collagen is stained light red.
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contractile dysfunction and fibrosis [16]. In this study, we
have shown that treatment with L-carnitine markedly attenu-
ated cardiac remodelling including hypertrophy and fibrosis
as well as hypertension in DOCA-salt hypertensive rats. Fur-
thermore, L-carnitine prevented the increase in plasma mal-
ondialdehyde concentrations indicating decreased oxidative
stress in DOCA-salt rats. However, the pronounced endothe-
lial dysfunction and the increased thoracic wall thickness,
characteristic of DOCA-salt hypertensive rats, were mini-
mally changed with L-carnitine treatment.
L-Carnitine plays a major role, as a cofactor, in the trans-
portation of free fatty acids from the cytosol to the mito-
chondria for adenosine triphosphate synthesis. An altered
metabolic substrate use in the failing heart also contributes
to the dysfunction of the mitochondrial electron transport
chain, resulting in enhanced production of superoxide [17].
Mitochondrial dysfunction and increased mitochondrial
superoxide production, preceding endothelial dysfunction,
might favour the development of hypertension [18]. Free rad-
icals also potentiate mitochondrial dysfunction by further
damaging mitochondrial DNA, with resultant impairment in
the synthesis of some components of the respiratory chain
and further increases in superoxide production [18–21].
The substrate usage pattern for cardiac energy shifts to
decreased fatty acid oxidation and increased glucose oxida-
tion within the myocardial mitochondria during the develop-
ment of pathophysiological conditions such as ischaemia,
hypertrophy and heart failure [22–24]. L-Carnitine, by allow-
ing efficient fatty acid transport, changes this energy shift
back to increased fatty acid oxidation so that the elevated
energy demands of the hypertensive heart can be met. This
shift with L-carnitine prevents the increase in production of
mitochondrial superoxide [25]. This potential of L-carnitine
to increase fatty acid oxidation in the myocytes while reduc-
ing oxidative stress provides a likely explanation for the
attenuation of cardiac remodelling observed in the current
study. L-Carnitine treatment improved heart function after
ischaemia and reperfusion injury [4], and also improved
heart rate regulation and ventricular size in streptozotocin-
diabetic rats [26]. In spontaneously hypertensive rats, oxida-
tive stress in heart, liver and plasma was decreased following
L-carnitine supplementation, although blood pressure was
unchanged and contractile responses of isolated blood vessels
were not measured [27]. In the current study, L-carnitine
attenuated cardiac hypertrophy, possibly due to antioxidant
and anti-inflammatory effects, but did not reverse vascular
hypertrophy. Myocardial fibrosis was also attenuated result-
ing in a reduced diastolic stiffness in the isolated heart studies.
However, the functional performance of the DOCA-salt rat
hearts was not significantly different to that of UNX controls;
heart failure is unlikely in this 4-week model, compared with
8-week DOCA-salt rats [15].
In the current study, L-carnitine treatment attenuated the
increases in the blood pressure of DOCA-salt hypertensive
rats. Several other studies have also proved the efficiency of
L-carnitine in reducing blood pressure in patients with pul-
monary hypertension [28], in rats with L-NAME-induced
hypertension [29] and in fructose-fed hypertensive rats [30].
The mechanisms by which L-carnitine can decrease blood
pressure include its role in enhancing fatty acid oxidation
[28] and the consequent role to reduce the production of
superoxide [25], and further increasing the availability
of nitric oxide [30]. In addition, the anti-hypertensive effects
of L-carnitine in this study may result from inhibition of
A B C D
Fig. 3. Haematoxylin and eosin staining showing infiltrating inflammatory cells in the left ventricular interstitial region (magnification, ·40) in
UNX (A), DOCA-salt (B), UNX + l-carnitine (C), DOCA-salt + l-carnitine (D)-treated rats.
A B C D
50 µm 50 µm 50 µm 50 µm
Fig. 4. Picrosirius red staining of thoracic aortic rings to define vascular smooth muscle (magnification, ·20) in UNX (A), DOCA-salt (B),
DOCA-salt + l-carnitine (C)-treated rats.
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inflammation, as inflammation is an integral part of the car-
diovascular remodelling observed in DOCA-salt hypertensive
rats [13,16]. Furthermore, plasma concentrations and cardiac
expression of inflammatory markers such as IL-6 and TNF-
a were reduced after L-carnitine treatment in L-NAME-
induced hypertensive rats [29]. Both the anti-inflammatory
and antioxidant properties of L-carnitine can explain the
reduced weight of the remnant kidney in DOCA-salt rats.
Renal hypertrophy was reduced and function improved
through the scavenging of free radicals and reducing tissue
inflammation in DOCA-salt hypertensive rats treated with
hemin, an up-regulator of haemoxygenase [31].
However, the pronounced endothelial dysfunction seen in
the DOCA-salt hypertensive rats in this study was not
altered by L-carnitine supplementation. Similar to the heart,
increased superoxide production is an important cause of
oxidative stress in the vasculature of the DOCA-salt hyper-
tensive rats. However, the major source of superoxide is the
mitochondria in the heart compared to the activation of
NADPH oxidase in the vasculature [32,33], although vascu-
lar xanthine oxidase and mitochondrial oxidation phosphor-
ylation complexes can contribute to vascular superoxide
production in DOCA-salt rats, especially in mesenteric resis-
tance arteries [34]. Since the primary role of L-carnitine is to
mediate the transport of fatty acids into the mitochondria of
cardiac muscle [35], L-carnitine controls oxidative stress by
improving mitochondrial function [25,35]. In the vasculature
of DOCA-salt rats, endothelin activation of NADPH oxi-
dase, acting via ETA receptors, increases superoxide produc-
tion [8,33]; L-carnitine does not appear to inhibit this
pathway but NADPH oxidase-independent pathways may
also be involved [36]. However, in the spontaneously hyper-
tensive rats, L-carnitine reduced endothelial dysfunction,
especially through its antioxidant properties [37,38]. In
streptozotocin-diabetic rats, L-carnitine partially restored
endothelium-dependent relaxation to acetylcholine with no
changes in responses to sodium nitroprusside [39]. In conclu-
sion, this study suggests that the mitochondrial respiratory
chain is a significant source of reactive oxygen species in the
heart but a relatively minor source in the vasculature. As a
consequence, L-carnitine attenuates cardiac remodelling more
than vascular remodelling because of its actions on the
mitochondria.
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